rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ENTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Entera Bio appoints Juan Arjona Ferreira to board of directors
      Oct 27Investing.comENTX
      Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
      Oct 27Yahoo FinanceENTX
      Entera Bio presents phase 2 data for oral osteoporosis drug
      Oct 13Investing.comENTX
      Entera Bio presents phase 2 osteoporosis data at ASBMR meeting
      Oct 13Investing.comENTX
      Entera Bio to present Phase 3 trial design for oral osteoporosis drug
      Oct 8Investing.comENTX
      Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting

      TEL AVIV, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that an additional presentation highlighting the clinical study design for its planned Phase 3 registrational trial of EB613 (oral PTH(1-34) tablet) will be presented at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9-12, 2026, at the John B. Hynes Veterans Memorial Conv

      Oct 8Yahoo FinanceENTX
      Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX) - Entera Bio (NA

      WSW, NY, October 7th, 2026, FinanceWireThe former Gilead and Amgen commercial leader takes her seat as Entera’s Phase 3 trial nears its initiation.Entera Bio Ltd. (NASDAQ:ENTX), a clinical-stage developer of oral

      Oct 7BenzingaAMGNENTXGILD
      Entera Bio Strengthens Board with Veteran Biopharma Leader

      Detailed price information for Entera Bio Ltd (ENTX-Q) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailENTX
      Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
      Oct 6Yahoo FinanceENTX
      Guggenheim Initiates Entera Bio at Buy With $11 Price Target

      Entera Bio (ENTX) has an average rating of buy and mean price target of $9.75, according to analysts

      Sep 25Yahoo FinanceENTX
      Guggenheim initiates Entera Bio stock with buy rating on oral peptide platform
      Sep 25Investing.comENTX
      Entera Bio Receives New Overweight Rating From Cantor Fitzgerald (NASDAQ: ENTX) - Entera Bio (NASDAQ:ENTX

      WSW, NY, September 23rd, 2026, FinanceWireEntera Bio Ltd. (NASDAQ:ENTX) has been initiated with coverage by Cantor Fitzgerald, in a report titled “No More Needles! An Oral PTH For Osteoporosis”, which assigned the

      Sep 23BenzingaENTX
      Entera Receives $9 Price Target and New ‘Outperform’ Rating From Leerink Partners (NASDAQ: ENTX)

      Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

      Sep 19The Globe and MailENTX
      Entera Receives $9 Price Target and New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX)
      Sep 18BenzingaENTX
      Entera to Participate in Upcoming Fall Investor Conferences

      TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be participating in the following upcoming fall investor conferences: 2026 Cantor Global Healthcare ConferenceFireside Chat: September 10, 2026 at 1:00 p.m. Eastern Time, Waldorf Astoria New York, 301 Park Avenue, New York, NY 2026 Leerink Partners Biopharma

      Aug 27Yahoo FinanceENTX
      Correction: Entera to Participate in Upcoming Fall Investor Conferences

      TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be participating in the following upcoming fall investor conferences: 2026 Cantor Global Healthcare ConferenceFireside Chat: September 10, 2026 at 1:00 p.m. Eastern Time, Waldorf Astoria New York, 301 Park Avenue, New York, NY Guggenheim Securities 3rd Annual

      Aug 27Yahoo FinanceENTX

      This is the newest page. Registered accounts read further back.